INTERCEPT Platelets

Phase III/IV

  • SPRINT Phase III
    • McCullough J, Vesole DH, Benjamin RJ et al.  Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial.  Blood 2004;104(5):1534-41.
      > View abstract
       
    • Murphy S, Snyder E, Cable R et al.  Platelet dose consistency and its effect on the number of platelet transfusions for support of thrombocytopenia: an analysis of the SPRINT trial of platelets photochemically treated with amotosalen HCl and ultraviolet A light.  Transfusion 2006;46(1):24-33.
      > View abstract
       
    • Pineda A, McCullough J, Benjamin RJ et al.  Pathogen inactivation of platelets with a photochemical treatment with amotosalen HCl and ultraviolet light: process used in the SPRINT trial.  Transfusion 2006;46(4):562-71.
      > View abstract
       
    • Snyder E, McCullough J, Slichter SJ et al.  Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial.  Transfusion 2005;45(12):1864-75.
      > View abstract
  • euroSPRITE Phase III
    • van Rhenen D, Gulliksson H, Cazenave JP et al.  Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial.  Blood 2003;101(6):2426-33.
      > View abstract
       
    • van Rhenen DJ, Gulliksson H, Cazenave JP et al.  Therapeutic efficacy of pooled buffy-coat platelet components prepared and stored with a platelet additive solution. Transfus Med 2004;14(4):289-95.
      > View abstract
  • EU Apheresis Study
    • Janetzko K, Cazenave JP, Kluter H et al. Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set. Transfusion 2005;45(9):1443-52.
      > View abstract
  • 7-Day Pilot Study
    • Simonsen AC, Johansson PI, Conlan MG et al.  Transfusion of 7-day-old amotosalen photochemically treated buffy-coat platelets to patients with thrombocytopenia: a pilot study. Transfusion 2006;46(3):424-33.
      > View abstract
  • TESSI (7-Day Platelets)
    • Lozano M, Knutson F, Tardivel R et al.  A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and UVA pathogen inactivation stored for 6 or 7 d prior to transfusion.  British Journal of Haematology 2011 May;153(3):393-401.
      > View abstract

Phase I/II

  • Snyder E, Raife T, Lin L et al.  Recovery and life span of 111indium-radiolabeled platelets treated with pathogen inactivation with amotosalen HCl (S-59) and ultraviolet A light.  Transfusion 2004;44(12):1732-40.
    > View abstract
     
  • Slichter SJ, Raife TJ, Davis K et al.  Platelets photochemically treated with amotosalen HCl and ultraviolet A light correct prolonged bleeding times in patients with thrombocytopenia.  Transfusion 2006;46(5):731-40.
    > View abstract

Additional Clinical Papers

  • Cazenave JP, Davis K, Corash L.  Design of clinical trials to evaluate the efficacy of platelet transfusion: the euroSPRITE trial for components treated with Helinx™ technology.  Seminars in Hematology 2001;38,4 (S11):46-54.
    > View abstract
     
  • Corash L.  Confounding variables and co-interventions in the design of clinical trials: real life experience.  Vox Sang 2002;83 (S1):261-266.
    > View abstract
     
  • Corash L, Lin JS, Sherman DC et al.  Determination of Acute Lung Injury After Repeated Platelet Transfusions.  Blood 2011 Jan 20;117(3):1014-20.
    > View abstract
     
  • Davis KB, Slichter SJ, Corash L.  Corrected count increment and percent platelet recovery as measures of posttransfusion platelet response: problems and a solution. Transfusion 1999;39(6):586-92.
    > View abstract

INTERCEPT Plasma

Phase III / IV

  • de Alarcon P, Benjamin R, Dugdale M et al.  Fresh frozen plasma prepared with amotosalen HCl (S-59) photochemical pathogen inactivation: transfusion of patients with congenital coagulation factor deficiencies.  Transfusion 2005;45(8):1362-72.
    > View abstract
     
  • Mintz PD, Bass NM, Petz LD, et al.  Photochemically treated fresh frozen plasma for transfusion of patients with acquired coagulopathy of liver disease.  Blood 2006;107(9):3753-60.
    > View abstract
     
  • Mintz PD, Neff A, MacKenzie M et al.  A randomized, controlled Phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura.  Transfusion 2006;46(10):1693-704.
    > View abstract

Phase I / II

  • Hambleton J, Wages D, Radu-Radulescu L et al.  Pharmacokinetic study of FFP photochemically treated with amotosalen (S-59) and UV light compared to FFP in healthy volunteers anticoagulated with warfarin.  Transfusion 2002;42(10):1302-7.
    > View abstract

RBC

Phase I / II (Current Process)

  • Cancelas JA, Dumont LJ, Rugg N et al.  Stored Red Blood Cell Viability is Maintained after Treatment with a Second Generation S-303 Pathogen Inactivation Process.  Transfusion 2011;51:11:2367-2376.
    > View abstract

Phase III (Original Process)

  • Benjamin RJ, McCullough J, Mintz PD et al.  Therapeutic efficacy and safety of red blood cells treated with a chemical process (S-303) for pathogen inactivation: a Phase III clinical trial in cardiac surgery patients.  Transfusion 2005;45(11):1739-49.
    > View abstract

Phase I / II (Original Process)

  • Rios JA, Hambleton J, Viele M et al.  Viability of red cells prepared with S-303 pathogen inactivation treatment.  Transfusion 2006;46(10):1778-86.
    > View abstract